Cardiology overview prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
===Drug Interactions=== | ===Drug Interactions=== | ||
*[[Cyclosporin]] co-administration is associated with a higher rate of [[myositis]] among statin users as a result of inhibition of [[CYP3A4]]. The exception is [[pravastatin]] in which this is not a problem. | *[[Cyclosporin]] co-administration is associated with a higher rate of [[myositis]] among statin users as a result of inhibition of [[CYP3A4]]. The exception is [[pravastatin]] in which this is not a problem. | ||
===Reducing non-myositis Muscle Pain== | |||
* [[Coenzyme Q]] can be used to reduce the incidence of non-[[myositis]] muscle pain. Several weeks of coenzyme Q should be given prior to trying the combination of the agent with statin therapy. | |||
==References== | ==References== | ||
Revision as of 17:31, 31 October 2011
|
Cardiology Overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Statin Therapy
Drug Interactions
- Cyclosporin co-administration is associated with a higher rate of myositis among statin users as a result of inhibition of CYP3A4. The exception is pravastatin in which this is not a problem.
=Reducing non-myositis Muscle Pain
- Coenzyme Q can be used to reduce the incidence of non-myositis muscle pain. Several weeks of coenzyme Q should be given prior to trying the combination of the agent with statin therapy.